Henry W Long
Overview
Explore the profile of Henry W Long including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
3857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li S, Song K, Sun H, Tao Y, Huang A, Bhatia V, et al.
bioRxiv
. 2025 Mar;
PMID: 40027790
Neuroendocrine prostate cancer (NEPC) arises primarily through neuroendocrine transdifferentiation (NEtD) as an adaptive mechanism of therapeutic resistance. Models to define the functional effects of putative drivers of this process on...
2.
Jiang Q, Braun D, Clauser K, Ramesh V, Shirole N, Duke-Cohan J, et al.
Cell
. 2025 Mar;
PMID: 40023154
Clear cell renal cell carcinoma (ccRCC), despite having a low mutational burden, is considered immunogenic because it occasionally undergoes spontaneous regressions and often responds to immunotherapies. The signature lesion in...
3.
Gokbayrak B, Altintas U, Lingadahalli S, Morova T, Huang C, Ersoy Fazlioglu B, et al.
Commun Biol
. 2025 Feb;
8(1):169.
PMID: 39905188
Enzalutamide is a potent second-generation antiandrogen commonly used to treat hormone-sensitive and castration-resistant prostate cancer (CRPC) patients. While initially effective, the disease almost always develops resistance. Given that many enzalutamide-resistant...
4.
Poluben L, Nouri M, Liang J, Chen S, Varkaris A, Ersoy-Fazlioglu B, et al.
Cell Rep
. 2024 Dec;
44(1):115089.
PMID: 39709604
Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in castration-resistant prostate cancer, but the extent to which they drive AR activity is unclear. We...
5.
DiCiaccio B, Seehawer M, Li Z, Patmanidis A, Bui T, Foidart P, et al.
Cell Rep
. 2024 Nov;
43(12):114991.
PMID: 39570746
We previously described that the KDM5B histone H3 lysine 4 demethylase is an oncogene in estrogen-receptor-positive breast cancer. Here, we report that KDM5A is amplified and overexpressed in basal breast...
6.
Yan P, Jimenez E, Li Z, Bui T, Seehawer M, Nishida J, et al.
Cancer Cell
. 2024 Oct;
42(11):1936-1954.e9.
PMID: 39366375
Aging is a pivotal risk factor for cancer, yet the underlying mechanisms remain poorly defined. Here, we explore age-related changes in the rat mammary gland by single-cell multiomics. Our findings...
7.
Duplaquet L, So K, Ying A, Pal Choudhuri S, Li X, Xu G, et al.
Cancer Cell
. 2024 Jul;
42(8):1352-1369.e13.
PMID: 39029464
Small cell lung cancers (SCLCs) are composed of heterogeneous subtypes marked by lineage-specific transcription factors, including ASCL1, NEUROD1, and POU2F3. POU2F3-positive SCLCs, ∼12% of all cases, are uniquely dependent on...
8.
Seehawer M, Li Z, Nishida J, Foidart P, Reiter A, Rojas-Jimenez E, et al.
Nat Cell Biol
. 2024 Jun;
26(7):1165-1175.
PMID: 38926506
KMT2C and KMT2D, encoding histone H3 lysine 4 methyltransferases, are among the most commonly mutated genes in triple-negative breast cancer (TNBC). However, how these mutations may shape epigenomic and transcriptomic...
9.
Singh P, Gu W, Madha S, Lynch A, Cejas P, He R, et al.
Cell Stem Cell
. 2024 May;
31(7):1038-1057.e11.
PMID: 38733993
Enteroendocrine cells (EECs) secrete serotonin (enterochromaffin [EC] cells) or specific peptide hormones (non-EC cells) that serve vital metabolic functions. The basis for terminal EEC diversity remains obscure. By forcing activity...
10.
Luo Q, Raulston E, Prado M, Wu X, Gritsman K, Whalen K, et al.
Nature
. 2024 May;
630(8015):198-205.
PMID: 38720074
Phosphoinositide-3-kinase-γ (PI3Kγ) is implicated as a target to repolarize tumour-associated macrophages and promote antitumour immune responses in solid cancers. However, cancer cell-intrinsic roles of PI3Kγ are unclear. Here, by integrating...